DetailsCategory: DNA RNA and CellsPublished on Saturday, 12 September 2020 14:07Hits: 360
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 --
- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater "On" Time without Troublesome Dyskinesia and Reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Scores, and Reduction in the Amount of Medications Up to Three Years in Patients with Parkinson's Disease
- 14 of 15 Patients Treated with NBIb-1817 Continued to Experience an Improvement in Disease Staging after Three Years, as Assessed by the Modified Hoehn & Yahr Scale
- Re-Initiation of Enrollment in Registrational RESTORE-1 Clinical Trial of NBIb-1817 Planned for Later this Year
SAN DIEGO, CA and CAMBRIDGE, MA, USA I September 11, 2020 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment with investigational gene therapy, NBIb-1817 (VY-AADC), showed sustained improvement in motor function including greater "On" time without troublesome dyskinesia, reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of medications in patients with Parkinson's disease.In the PD-1101 study, NBIb-1817 reduced average "Off" time by up to -1.91 hours and improved average "On" time without troublesome dyskinesia by up to +2.23 hours in patients with advanced Parkinson's disease after three years across three cohorts. In addition, 14 out of 15 patients treated with NBIb-1817 continued to show an improvement in disease staging after three years, as assessed by the modified Hoehn & Yahr scale. These new data, along with two-year data from another open-label Phase Ib trial, PD-1102, were presented today at the MDS Virtual Congress 2020, September 1216, 2020 (www.mdscongress.org/Congress/Registration.htm).
In data from the three-year PD-1101 trial, the one-time treatment with NBIb-1817 showed sustained reduction in diary "Off" time by an average of -0.15 to -1.91 hours (baseline 4.28 to 4.93 hours) and improved diary "On" time without troublesome dyskinesia by an average of +0.26 to +2.23 hours (baseline 10.32 to 10.46 hours) across the cohorts as reported by 15 patients with advanced Parkinson's disease. NBIb-1817 also showed sustained improvement in motor function after three years, as measured by UPDRS Part III off medication scores, by -10.2 to -19.0 points (baseline 35.8 to 38.2 points) across the cohorts, per clinician assessment. Requirements for Parkinson's disease medications were also reduced in cohorts 2 and 3 (daily levodopa-equivalent dose reductions, average of -322.0 and -441.2 mg/day, respectively; baseline 1507.0 and 1477.0 mg/day, respectively). Two-year data from the PD-1102 trial for 7 patients showed that NBIb-1817 reduced diary "Off" time by an average of -3.2 hours and increased diary good "On" time by +2.1 hours (baselines 9.3 hours and 6.6 hours, respectively). In this study, NBIb-1817 showed sustained improvement in motor function after two years, with improved UPDRS Part III off medication scores of -12.0 points (baseline 34.4). Requirements for Parkinson's disease medications were also reduced (daily levodopa-equivalent dose reduction, average of -439.5 mg/day; baseline 1500.9 mg/day). Preliminary safety data from both studies suggest that NBIb-1817 was well-tolerated, with no study drug-related serious adverse events (SAEs) reported. The most common adverse events reported were headache, hypoesthesia, and musculoskeletal pain (PD-1101), and upper respiratory tract infection, headache, nausea, and depression (PD-1102).
"It is promising to see that after three years, a single administration of one-time investigational gene therapy treatment NBIb-1817 showed sustained reduction in 'Off' time, as well as improvement in 'On' time without troublesome dyskinesia and other measures of motor function in patients with Parkinson's disease," said Chad Christine, M.D., primary author, a lead investigator of the study and Professor of Neurology at the University of California, San Francisco (UCSF) Weill Institute for Neurosciences. "Parkinson's disease patients' motor function would be expected to worsen over three years, making these results very encouraging. The standard of care for advanced Parkinson's disease has not significantly changed in decades and it is our hope that NBIb-1817 has the potential to become the first gene therapy for Parkinson's disease."
Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disorder that affects approximately one million people in the U.S. and six million people worldwide. It is characterized by a loss of dopamine from neuronal degeneration, with a concomitant loss of the aromatic L-amino acid decarboxylase (AADC) enzyme required to synthesize dopamine in the brain, leading to associated impairment in motor, neuropsychiatric, and autonomic functions.
"We are pleased that the results from these studies show that one-time treatment with investigational NBIb-1817 may help restore the brain's ability to convert levodopa into dopamine," said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "Our hope is that NBIb-1817 will help patients experience less 'Off' time and more 'On' time and improve motor symptom control. We plan to re-initiate enrollment in our registrational RESTORE-1 clinical trial with NBIb-1817 this year and look forward to further evaluating NBIb-1817 in patients with Parkinson's disease."
NBIb-1817 is an investigational recombinant adeno-associated viral serotype 2 vector encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine.
"We are encouraged by the congruence of long-term data, including clinician- and patient-reported clinical outcomes in our clinical studies," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of Research and Development at Voyager Therapeutics. "These results are promising and show that the approach has the potential to transform the treatment of Parkinson's disease, and help improve the lives of patients and their families."
Additional information about PD-1101 and PD-1102 will be available on demand for registered participants through October 1, 2020 on the MDS meeting website (www.mdscongress.org/Congress/Registration.htm).
About Parkinson's Disease and NBIb-1817 (VY-AADC) Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately one million people in the U.S. and six million people worldwide. It is characterized by a loss of dopamine and neuronal degeneration with a concomitant loss of the aromatic L-amino acid decarboxylase (AADC) enzyme required to synthesize dopamine in the brain, leading to associated impairment in motor, neuropsychiatric, and autonomic functions. Dopamine is a chemical "messenger" that is produced in the brain and is involved in the control of movement. It is made when AADC converts the chemical levodopa to dopamine. As Parkinson's disease progresses, there is less AADC enzyme in parts of the brain where levodopa is converted to dopamine.
NBIb-1817 is an investigational recombinant adeno-associated viral (AAV) serotype 2 vector encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine. NBIb-1817 is administered into the brain using intraoperative monitoring with magnetic resonance imaging (MRI)-facilitated targeted delivery.
About the RESTORE-1 Clinical TrialPaused temporarily in April 2020 due to the COVID-19 pandemic, Neurocrine Biosciences and Voyager Therapeutics plan to re-initiate RESTORE-1, a Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial, to evaluate the safety and efficacy of NBIb-1817 in patients who have been diagnosed with Parkinson's disease for at least four years and have at least three hours of "Off" time during the day as measured by a validated self-reported patient diary.
For more information about the RESTORE-1 clinical trial, including eligibility criteria, please visit clinicaltrials.gov and restore1study.com.
About the RESTORE-2 Clinical TrialPreparations are ongoing for the RESTORE-2 global registrational trial that will include clinical sites within and outside the U.S.
About Neurocrine Biosciences and Voyager Therapeutics Strategic CollaborationIn 2019, Neurocrine Biosciences and Voyager Therapeutics entered into a strategic collaboration focused on the development and commercialization of gene therapy programs, VY-AADC for Parkinson's disease and VY-FXN01 for Friedreich's ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences' expertise in neuroscience, drug development and commercialization with Voyager's innovative gene therapy programs targeting severe neurological diseases.
About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
About Voyager TherapeuticsVoyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases. For more information on Voyager, please visit the company's website at http://www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.
SOURCE: Voyager Therapeutics
Read this article:
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational...
- Unlocking Flow: The Neuroscience of Creative Bliss - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Revolutionizing Glioblastoma Treatment - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Decoding spontaneous thoughts from the brain via machine learning - EurekAlert - April 15th, 2024 [April 15th, 2024]
- Reducing Toxic AI Responses - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Advancing the neuroscience of human pregnancy - Nature.com - April 15th, 2024 [April 15th, 2024]
- Angela Bryan Awarded Hazel Barnes Prize | Psychology and Neuroscience - University of Colorado Boulder - April 15th, 2024 [April 15th, 2024]
- How Old Are You in Your Head? The Neuroscience of Subjective Age Reveals How to Stay Mentally Young - Inc. - April 15th, 2024 [April 15th, 2024]
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of ... - PR Newswire - April 15th, 2024 [April 15th, 2024]
- Those Who Use Willpower Deemed More Trustworthy - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- How Sex and Gender Shape Our Cognition - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- War's Toll on the Brain: Widespread PTSD and Anxiety Among Ukrainians - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Paints and Pesticides Linked to ALS Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- AI STORIES: A New Vision for AI and Narratives - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Neuroscience Breakthrough Unveils How We Learn and Remember - SciTechDaily - April 15th, 2024 [April 15th, 2024]
- Pregnancy's Toll: Accelerated Aging in Young Mothers - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Learning and Memory Formation's Molecular Basis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Acetaminophen in Pregnancy Not Linked to Autism, ADHD Risk - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Childhood Loneliness Linked to Later Psychosis - Neuroscience News - April 15th, 2024 [April 15th, 2024]
- Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share - Defense World - March 29th, 2024 [March 29th, 2024]
- International Brain Research Organisation (IBRO) Diversity Grants 2024 Opportunity Desk - Opportunity Desk - March 29th, 2024 [March 29th, 2024]
- Hereditary Alzheimer's Transmitted Via Bone Marrow Transplants - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Household Chemicals Linked to Brain Health Risks - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Cheers to Longevity: Couples Who Drink Together, Live Longer - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Sleeplessness Makes You Feel Up To Ten Years Older - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Aging Brain Cells Have Prolonged Death Process - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Anxiety Drives Wishful Thinking to Risky Levels - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Prolonged Progestogen Use Linked to Brain Tumor Risk - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- The Genetic Secrets of Neuron Formation - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Yahoo Finance - March 29th, 2024 [March 29th, 2024]
- Big research, little time: Medical neuroscience student wins 3 Minute Thesis finals - Dal News - March 29th, 2024 [March 29th, 2024]
- The new NeuroAI - Nature.com - March 29th, 2024 [March 29th, 2024]
- Exploring Aphantasia: The Mind Without a Mental Picture - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Altered Brain pH Linked to Cognitive Disorders - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Emotion vs. Reason: Rethinking Decision-Making - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- DNA Damage and Inflammation Key to Memory Formation - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Embracing Neurodiversity: Beyond Stigma to Strength - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Devil in the Details: The Visual World of Prosopometamorphopsia - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Rockefeller Neuroscience Institute receives $2M grant for ultrasound drug addiction treatments - Health Imaging - March 29th, 2024 [March 29th, 2024]
- Empathy Begins in Infancy - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Mapping Brain Activity with Brain-Computer Interface Technology - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Want Better Mental Focus? Neuroscience Just Found This Simple, Joyful Activity Helps Your Brain Concentrate - Inc. - March 29th, 2024 [March 29th, 2024]
- The neuroscience of groove: Why certain rhythms make us want to dance - PsyPost - March 29th, 2024 [March 29th, 2024]
- High Rates of Suicidal Ideation in Rural Black Men - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Harmony in Chaos: How BPD Influences Music Tastes - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- WVU Rockefeller Neuroscience Institute receives $2M Grant - WDTV - March 29th, 2024 [March 29th, 2024]
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024 [March 29th, 2024]
- Neuroscience and Society Series: Aligning Science with the Public's Values - The Hastings Center - March 29th, 2024 [March 29th, 2024]
- Hardwiring Your Brain: The Neuroscience Of Behaviour Change | TheHealthSite.com - TheHealthSite - March 29th, 2024 [March 29th, 2024]
- Refined Carb Intake's Effect on Facial Attractiveness - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Linking Childhood Adversity to Adult Mental Health - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Overnight neuronal plasticity and adaptation to emotional distress - Nature.com - March 11th, 2024 [March 11th, 2024]
- Less Obesity and Depression in NPD Individuals - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Unlocking Creative Flow: How the Brain Enters the Zone - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Self-Control, Not Impulsivity, Paves the Way to Power - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- 3D Maps Reveal Molecular Complexities of the Brain - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Loneliness Linked to Personality Disorders - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Gen Z's Climate Anxiety: A Call for Action and Hope - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Decoding Emotions: Beyond Senses in the Human Brain - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Brain Circuit Balances Speech and Breath - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Schizophrenia and Aging Share Brain Changes - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Monitoring Spinal Cord Activity During Surgery in Real-Time - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Scientists team up with jazz musicians to reveal the neuroscience of creative flow - PsyPost - March 11th, 2024 [March 11th, 2024]
- Peer Pressure Persists Through Adulthood - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Mary Bartlett Bunge, 92, Dies; Pioneer in Spinal Injury Treatment - The New York Times - March 11th, 2024 [March 11th, 2024]
- Rethinking Reminiscence: Theater's Ageism Dilemma Unveiled - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- PTSD: Virtual Reality and Magnetic Stimulation Provide Relief - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- The Partisan Morality Divide: When Politics Shapes Right and Wrong - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Biological Sciences Professor Terrence Sejnowski Wins Brain Prize - University of California San Diego - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - afp.com - March 11th, 2024 [March 11th, 2024]
- Substance Abuse Beyond Dopamine and Impulsivity - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - Business Wire - March 11th, 2024 [March 11th, 2024]
- Dal study of football players sheds light on how concussions affect the brain - Yahoo Canada Sports - March 11th, 2024 [March 11th, 2024]
- Hebrew University's Haim Sompolinsky awarded prestigious Brain Prize for pioneering neuroscience research - The Times of Israel - March 11th, 2024 [March 11th, 2024]
- Harvard neuroscientist Haim Sompolinsky awarded Brain Prize - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Rhythm in the Brain: Music Exposure Influences Rhythmic Interpretation - Neuroscience News - March 11th, 2024 [March 11th, 2024]
- Physicist Haim Sompolinsky first Israeli to win largest brain science research prize - The Times of Israel - March 11th, 2024 [March 11th, 2024]
- Prestigious 2024 Brain Prize awarded to Hebrew University's Prof. Haim Sompolinsky by Lundbeck Foundation - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Pioneering work in computational and theoretical neuroscience is awarded the world's largest brain research prize - EurekAlert - March 11th, 2024 [March 11th, 2024]
- Role of AI in Neuroscience Research and Understanding of the Human Brain - Medriva - February 13th, 2024 [February 13th, 2024]
- Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, - EIN News - February 13th, 2024 [February 13th, 2024]